Gencurix Inc. (229000.KQ)

KRW 1446.0

(-0.69%)

Market Cap (In KRW)

22.84 Billion

Revenue (In KRW)

2.6 Billion

Net Income (In KRW)

-19.26 Billion

Avg. Volume

583.64 Thousand

Currency
KRW
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1131.0-6340.0
PE
-
EPS
-
Beta Value
0.154
ISIN
KR7229000005
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Specialties
CEO
Sung-Rai Cho
Employee Count
-
Website
https://www.gencurix.com
Ipo Date
2017-04-05
Details
Gencurix Inc. provide diagnostic solutions in South Korea. Its products include GenesWell BCT, a prognosis diagnostic test for breast cancer; GenesWell ddEGFR Mutation Test, a companion test for lung cancer; Droplex, a genetic test that detects DNA mutations; eDX, an early diagnosis for cancer with liquid biopsy; GenePro COVID-19 detection test; GenePro SARS-CoV-2 Test kit; GenoCTC (circulating tumor cell isolator); GenePro LAMP test solution for rapid, convenient and simple detection of various infectious diseases; and GenePro LAMP Cycler, a device for loop-mediated isothermal amplification. The company was founded in 2011 and is headquartered in Seoul, South Korea.

More Stocks